A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Start Date17 Jan 2025

Sponsor / Collaborator

National Cancer Institute

NCT06665217 / Not yet recruitingPhase 2IIT

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.

Start Date01 Jan 2025

Sponsor / Collaborator

Navy General Hospital

NCT06441097 / Not yet recruitingPhase 2IIT

A Study to Evaluate the Efficacy and Safety of Genotype-guided Targeted Agents in Combination With POLA-RCHP VERSUS POLA-RCHP in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Start Date31 Dec 2024

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

100 Clinical Results associated with Lenalidomide

100 Translational Medicine associated with Lenalidomide

100 Patents (Medical) associated with Lenalidomide

5,961

Literatures (Medical) associated with Lenalidomide

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations

Article

Author: Wang, Xin ; Qu, Shiqiang ; Gale, Robert Peter ; Qin, Tiejun ; Pan, Lijuan ; Xiao, Zhijian ; Jia, Yujiao ; Li, Bing ; Jiao, Meng ; Xu, Zefeng ; Gao, Qingyan

Myelodysplastic syndromes (MDS) patients with DEAD-box helicase 41 (DDX41) mutations have been reported to be treated effectively with lenalidomide; however, there are no randomized studies to prove it. Venetoclax and azacitidine are safe and effective in high-risk MDS/AML. In this study, we evaluated the efficacy of venetoclax and azacitidine combination therapy in eight consecutive MDS patients with DDX41 mutations at our centre from March 2021 to November 2023. We retrospectively analyzed the genetic features and clinical characteristics of these patients. Our findings suggest that MDS patients with DDX41 mutation may benefit from the therapy, for six subjects received this regimen as initial therapy and five of the six subjects achieved complete remission.

31 Dec 2024·Human vaccines & immunotherapeutics

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Article

Author: Stathis, Anastasios ; Zucca, Emanuele ; Pirosa, Maria Cristina

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.

01 Dec 2024·BIOORGANIC CHEMISTRY

Design, synthesis, and in silico insights of novel N’-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors

Article

Author: Hammad, Sherif F ; Ali, Mamdouh M. ; Maklad, Raed M. ; Mahmoud, Abeer E ; Elsayed, Zainab M. ; El Kerdawy, Ahmed M ; Elsawi, Ahmed E. ; El Kerdawy, Ahmed M. ; Elsawi, Ahmed E ; Maklad, Raed M ; Mahmoud, Abeer E. ; Elsayed, Zainab M ; Eldehna, Wagdy M ; Ali, Mamdouh M ; Habib, Youmna A. ; Barghash, Mohamed F. ; Eldehna, Wagdy M. ; Habib, Youmna A ; Khalil, Amira ; Hammad, Sherif F. ; Barghash, Mohamed F ; Rashed, Mahmoud

Vascular endothelial growth factor (VEGF) is a crucial key factor in breast tumorigenesis. VEGF plays an important role in angiogenesis, tumor proliferation, and metastasis. Herein, we report the design and synthesis of twenty-one novel piperidine/oxindole derivatives as potential VEGFR-2 inhibitors. The designed compound library aimed to occupy the binding site of VEGFR-2 in a similar binding pattern to that of the reference VEGFR-2 inhibitor Sorafenib. The synthesized compounds were biologically evaluated for their cytotoxic effects against two breast cancer cell lines (MCF-7 and MDA-MB-468). Compounds 12e and 6n were the most potent cytotoxic derivatives against the former and the latter cell lines, showing IC₅₀ values of 8.00 and 0.60 µM, respectively. Furthermore, all the synthesized compounds were evaluated for their inhibitory activities towards VEGFR-2, with compound 12e showing the most potent activity with an IC₅₀ value of 45.9 nM, surpassing the reference standard Sorafenib (IC₅₀ = 48.6 nM). Additionally, compound 6n emerged as the top performer when tested with the other most promising compounds for their cytotoxic effects on HUVEC (IC₅₀ = 28.77 nM). The designed library of compounds was subjected to molecular docking and molecular dynamic simulations, which revealed key binding interactions within the VEGFR-2 active site, including hydrogen bonding with Cys919, Glu885, and Asp1046 residues. Moreover, in silico predictions of physicochemical and pharmacokinetic properties for the target compounds indicated favorable drug-like characteristics.

585

News (Medical) associated with Lenalidomide

14 Nov 2024

·www.globenewswire.com

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd aloneIf approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). A final decision is expected in the coming months. Dietmar Berger, M.D., Ph.D.Chief Medical Officer, Global Head of Development at Sanofi“The positive CHMP opinion is an important step forward for people with transplant-ineligible newly diagnosed multiple myeloma for whom effective front-line therapy may improve long-term outcomes. If approved, this Sarclisa-based combination could establish a new standard-of-care treatment approach for patients in the EU, helping to address a critical care gap in multiple myeloma treatment, and reinforcing Sarclisa’s potential as the anti-CD38 therapy of choice.” In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the first line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Sarclisa is currently approved in two indications for the treatment of certain adult patients with relapsed or refractory MM in more than 50 countries, including the US and EU. First positive global phase 3 study combining anti-CD38 therapy with VRd to significantly improve PFS versus VRd alone in transplant-ineligible NDMM supports CHMP decisionThe positive CHMP opinion is based on data from the IMROZ phase 3 study, which was presented at the American Society of Clinical Oncology 2024 annual meeting, European Hematology Association 2024 meeting, and published in The New England Journal of Medicine. IMROZ is the first global phase 3 study of a CD38 monoclonal antibody in combination with standard-of-care VRd to significantly improve progression-free survival (PFS) versus VRd alone. The safety and tolerability of Sarclisa observed was consistent with the established safety profile of Sarclisa and VRd with no new safety signals. About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US FDA. Currently Sarclisa is approved in more than 50 countries, including the US and EU, across two indications; Sarclisa is approved under an additional indication in the US. In Europe, based on the ICARIA-MM phase 3 study, Sarclisa is approved in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed refractory MM (RRMM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor and who progressed on last therapy. Based on the IKEMA phase 3 study, Sarclisa is also approved in 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with RRMM who have received 1–3 prior lines of therapy and in the European Union for patients with MM who have received at least 1 prior therapy. In the US, Sarclisa is also approved in combination with VRd as a first line treatment option for adult patients with NDMM who are not eligible for ASCT, based on the IMROZ phase 3 study. Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous administration method for Sarclisa in clinical studies. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery. In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centered on difficult-to-treat cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well as gastrointestinal and lung cancers. For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov. About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com Investor RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comArnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

Phase 3Drug ApprovalASCOClinical ResultImmunotherapy

13 Nov 2024

·www.businesswire.com

Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463

PARIS--( BUSINESS WIRE )-- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform , will be holding a webinar to run through new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of EO2463, for the treatment of patients with either newly diagnosed, previously untreated follicular lymphoma (FL) [EO2463 monotherapy], or FL and marginal zone lymphoma relapsed/refractory disease [EO2463 in combination with lenalidomide/rituximab]. The data is being presented in two posters at the 66 th American Society of Hematology (ASH) Annual Meeting and Conference by Jose Caetano (JC) Villasboas Bisneto, MD, PhD, principal study investigator at the Mayo Clinic, and Stephen Smith, MD, hematologist and medical oncologist at the Fred Hutchinson Cancer Center. Poster details Abstract #1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab Abstract #4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/SIDNEY Study Webinar details are as follows: Date : 12 December 2024 Time : 9.30am-10.35am PT / 12.30pm-1.35pm ET / 5.30pm-6.35pm UK / 6.30pm-7.35pm CET Presenters : Pierre Belichard PhD, CEO, Enterome Laurent Chene PhD, Head of Drug Discovery, Enterome Jose Caetano (JC) Villasboas Bisneto, MD, PhD, Mayo Clinic Jan Fagerberg, MD, PhD, CMO of Enterome will also be present for the Q&A session following the presentation. To attend, please register your details at enterome@vigoconsulting.com . Questions can be submitted at any time during the presentation. Background About EONHL1-20/SIDNEY: SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as a monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with iNHL. The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). For more information on the study, visit www.Clinicaltrials.gov , reference: NCT04669171 . About EO2463: EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms. About Enterome Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. Enterome’s first-in-class drug candidates are based on synthetically produced, commensal-derived peptides that modulate the immune system by closely mimicking the structure of specific antigens. The company’s oncology pipeline includes the following OncoMimics™ peptide-based immunotherapies: EO2463, currently in the Phase 2 ‘SIDNEY’ clinical trial for indolent non-Hodgkin lymphomas, has shown a favorable safety profile with promising early signs of efficacy; EO2401, administered in combination with nivolumab and bevacizumab, has demonstrated clinical activity in approximately one-third of patients with recurring glioblastoma in the completed Phase 1/2 ‘ROSALIE’ study; EO4010 is being evaluated in metastatic colorectal cancer in the Phase 1/2 ‘AUDREY’ study. Enterome is headquartered in Paris, France. Since its inception, the company has raised a total of €118 million from Europe- and US-based life science investors, and more than €100 million through pharmaceutical partnerships. For more information, visit: www.enterome.com

ImmunotherapyPhase 2Clinical ResultASHPhase 1

13 Nov 2024

·firstwordpharma.com

Sanofi's fight for myeloma drug Sarclisa wins reprieve from NICE

The UK's National Institute for Health and Care Excellence (NICE) has agreed to re-assess Sanofi's Sarclisa (isatuximab) combination therapy for relapsed and refractory multiple myeloma, after previously rejecting the treatment in its final draft guidance.Sanofi is looking to get a NICE recommendation for using the anti-CD38 therapy in a subgroup of the population within its existing marketing authorisation – specifically in fourth-line adult patients who have had Revlimid (lenalidomide) and a proteasome inhibitor, and whose disease progressed on their last treatment.In June, the agency issued final draft guidance not recommending for this group. At the time, Sanofi said Sarclisa plus pomalidomide and dexamethasone (Isa-Pd) has become widely used in England and Wales through the Cancer Drugs Fund, with over 1700 patients receiving it. However, the company believed that under NICE's current rules, Isa-Pd would not be considered cost-effective, even if the price of Sarclisa was "offered at zero price," arguing that the existing system doesn't fairly evaluate combination medicines like Isa-Pd.Sanofi along with Myeloma UK and the UK Myeloma Society successfully appealed that decision, which now opens the door to a third NICE committee meeting. Specifically, the appeal panel upheld four of Sanofi's grounds, including that NICE's evaluation methods have evolved since the combination first entered the Cancer Drugs Fund."We are encouraged by NICE's decision to uphold our appeal, which will be welcomed by clinicians, patient groups and patients for whom the potential loss of a multiple myeloma treatment will be devastating," said Anju Bhalla, head of oncology and haematology at Sanofi UK and Ireland. "This appraisal has been protracted and complex for several reasons, but we remain hopeful of a positive outcome at the third time of sitting around the table together."The efficacy of Isa-Pd was evaluated in the Phase III ICARIA-MM trial. Patients treated with the combo lived without disease progression for an average of 12.4 months, nearly six months longer than those on Pd alone, representing a benefit of 47.6%. Overall survival for Isa-Pd patients was 33.3 months, nearly double the 17.7 months for those on Pd alone.

Phase 3Clinical Result

100 Deals associated with Lenalidomide

External Link

KEGG	Wiki	ATC	Drug Bank
D04687	Lenalidomide	L04AX04	DB00480

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Marginal Zone B-Cell Lymphoma	US	Bristol Myers Squibb Co.	28 May 2019
Adult T-Cell Leukemia-Lymphoma	JP	Bristol-Myers Squibb KK	02 Mar 2017
Chromosome 5q Deletion Syndrome	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	EU	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	IS	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	LI	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	NO	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Multiple Myeloma	US	Bristol Myers Squibb Co.	29 Jun 2006
Myelodysplastic Syndromes	US	Bristol Myers Squibb Co.	27 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plasmacytoma	Phase 3	US	Millennium Pharmaceuticals, Inc.	01 Dec 2015
Plasmacytoma	Phase 3	US	Biologics, Inc.	01 Dec 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	US	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CN	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	JP	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	AU	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	BE	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CA	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	CZ	Celgene Corp.	17 Feb 2015
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Phase 3	FR	Celgene Corp.	17 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Multiple Myeloma	-	Lenalidomide	juhxszphoz(tqqpwfodju) = teuiiphyhn nlomhffxgj (yrcufbpqyh, 1 - 12)	-	09 Dec 2024
ASH2024	Not Applicable	Recurrent Multiple Myeloma	-	Belantamab mafodotin 1.4 mg/kg	qfdppmptmq(uxpelkpgqf) = 89.5% experienced blurred vision ysetrctjxq (hrtezmodpn ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Recurrent Multiple Myeloma	-	Belantamab mafodotin 1.9 mg/kg		-	09 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Ixazomib, Lenalidomide Plus Dexamethasone (IRd)	jddlgoxtae(fwedjftwab) = 6(7.0%) pts in the IRd group zoramzqtsu (xlebnyjmrn ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Bortezomib, Lenalidomide Plus Dexamethasone (VRd)		-	09 Dec 2024
NCT03319667 (IMROZ, ASH2024)	Phase 3	Multiple Myeloma	446	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)	mnfkeszbao(ytnzigeyle) = okiyqitomn fbyvaxlxxq (rcgwkchorv ) View more	Positive	09 Dec 2024
NCT03617731 (GMMG-HD7, ASH2024)	Phase 3	Multiple Myeloma CD38	662	Isatuximab, Lenalidomide, Bortezomib, Dexamethasone	oqqykiqdjs(buaqxbnymv) = lyimzxomwg gwcufeddkp (slraschbnf, 95% CI 0.52 - 0.94) View more	Positive	09 Dec 2024
NCT03617731 (GMMG-HD7, ASH2024)	Phase 3	Multiple Myeloma CD38	662	Lenalidomide, Bortezomib, Dexamethasone	oqqykiqdjs(buaqxbnymv) = hpqimkclgm gwcufeddkp (slraschbnf, 95% CI 46 - 48) View more	Positive	09 Dec 2024
REST (ASH2024)	Phase 2	Multiple Myeloma First line	51	Isatuximab-Bortezomib-Lenalidomide-Dexamethasone	pfbeoqhebh(enilagolax) = cxbccdenkc nqelwpzpra (lsmromzgdp, 82 - 99) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Lenalidomide	pmjzsqvcba(ksuzrymhep) = cdftkmkdfx drkvmhvpfv (xwujtkqqyb ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	78	CyBorD induction + HD-Mel + single ASCT + lenalidomide maintenance	ctmuylobjq(myxwkvzxkd) = okxijbyeul tjisysswhj (oihhamkumj, 70 - 88) View more	Positive	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd)	yaqhpvufxx(ilbcamczhz) = usqfegokms auwpzqpmwt (bzmooicucb ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	DVRd-DR	yaqhpvufxx(ilbcamczhz) = xwcbxyojoc auwpzqpmwt (bzmooicucb ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Daratumumab, Lenalidomide, Bortezomib, Dexamethasone (D-RVd)	duqxxjznwu(hegwkmfzqd) = 82% ntcczvujvl (ovkjmyejjv ) View more	-	08 Dec 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis